These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 1352033)

  • 1. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides.
    Bennett CF; Chiang MY; Chan H; Shoemaker JE; Mirabelli CK
    Mol Pharmacol; 1992 Jun; 41(6):1023-33. PubMed ID: 1352033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice.
    Saijo Y; Perlaky L; Wang H; Busch H
    Oncol Res; 1994; 6(6):243-9. PubMed ID: 7865900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural requirements for cationic lipid mediated phosphorothioate oligonucleotides delivery to cells in culture.
    Bennett CF; Mirejovsky D; Crooke RM; Tsai YJ; Felgner J; Sridhar CN; Wheeler CJ; Felgner PL
    J Drug Target; 1998; 5(3):149-62. PubMed ID: 9606005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular pharmacology of p120 antisense oligodeoxynucleotide phosphorothioate ISIS 3466.
    Saijo Y; Perlaky L; Valdez BC; Wang H; Henning D; Busch H
    Oncol Res; 1993; 5(8):283-91. PubMed ID: 8012060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides.
    Bennett CF; Condon TP; Grimm S; Chan H; Chiang MY
    J Immunol; 1994 Apr; 152(7):3530-40. PubMed ID: 7511650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth inhibition of human tumor cell lines by antisense oligonucleotides designed to inhibit p120 expression.
    Perlaky L; Saijo Y; Busch RK; Bennett CF; Mirabelli CK; Crooke ST; Busch H
    Anticancer Drug Des; 1993 Feb; 8(1):3-14. PubMed ID: 8476501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic properties of several novel oligonucleotide analogs in mice.
    Crooke ST; Graham MJ; Zuckerman JE; Brooks D; Conklin BS; Cummins LL; Greig MJ; Guinosso CJ; Kornbrust D; Manoharan M; Sasmor HM; Schleich T; Tivel KL; Griffey RH
    J Pharmacol Exp Ther; 1996 May; 277(2):923-37. PubMed ID: 8627575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced metastatic ability of TNF-alpha-treated malignant melanoma cells is reduced by intercellular adhesion molecule-1 (ICAM-1, CD54) antisense oligonucleotides.
    Miele ME; Bennett CF; Miller BE; Welch DR
    Exp Cell Res; 1994 Sep; 214(1):231-41. PubMed ID: 7915992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms.
    Chiang MY; Chan H; Zounes MA; Freier SM; Lima WF; Bennett CF
    J Biol Chem; 1991 Sep; 266(27):18162-71. PubMed ID: 1680858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides.
    Crooke RM; Graham MJ; Cooke ME; Crooke ST
    J Pharmacol Exp Ther; 1995 Oct; 275(1):462-73. PubMed ID: 7562586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral activity and ocular kinetics of antisense oligonucleotides designed to inhibit CMV replication.
    Henry SP; Miner RC; Drew WL; Fitchett J; York-Defalco C; Rapp LM; Levin AA
    Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2646-51. PubMed ID: 11581212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5' cholesterol-conjugated phosphorothioate antisense oligonucleotides.
    Alahari SK; Dean NM; Fisher MH; Delong R; Manoharan M; Tivel KL; Juliano RL
    Mol Pharmacol; 1996 Oct; 50(4):808-19. PubMed ID: 8863825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spontaneous and cationic lipid-mediated uptake of antisense oligonucleotides in human monocytes and lymphocytes.
    Hartmann G; Krug A; Bidlingmaier M; Hacker U; Eigler A; Albrecht R; Strasburger CJ; Endres S
    J Pharmacol Exp Ther; 1998 May; 285(2):920-8. PubMed ID: 9580645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of human cytomegalovirus replication in a human retinal epithelial cell model by antisense oligonucleotides.
    Detrick B; Nagineni CN; Grillone LR; Anderson KP; Henry SP; Hooks JJ
    Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):163-9. PubMed ID: 11133862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus.
    Marcusson EG; Bhat B; Manoharan M; Bennett CF; Dean NM
    Nucleic Acids Res; 1998 Apr; 26(8):2016-23. PubMed ID: 9518498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes.
    Nestle FO; Mitra RS; Bennett CF; Chan H; Nickoloff BJ
    J Invest Dermatol; 1994 Oct; 103(4):569-75. PubMed ID: 7930684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific inhibition of influenza virus RNA polymerase and nucleoprotein genes expression by liposomally endocapsulated antisense phosphorothioate oligonucleotides: penetration and localization of oligonucleotides in clone 76 cells.
    Hatta T; Takai K; Nakada S; Yokota T; Takaku H
    Biochem Biophys Res Commun; 1997 Mar; 232(2):545-9. PubMed ID: 9125219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological effects and cellular uptake of c-myc antisense oligonucleotides and their cationic liposome complexes.
    Kanamaru T; Takagi T; Takakura Y; Hashida M
    J Drug Target; 1998; 5(4):235-46. PubMed ID: 9713974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice.
    Yu RZ; Zhang H; Geary RS; Graham M; Masarjian L; Lemonidis K; Crooke R; Dean NM; Levin AA
    J Pharmacol Exp Ther; 2001 Feb; 296(2):388-95. PubMed ID: 11160622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302).
    Glover JM; Leeds JM; Mant TG; Amin D; Kisner DL; Zuckerman JE; Geary RS; Levin AA; Shanahan WR
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1173-80. PubMed ID: 9316823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.